2026 Annual Updates in Hematology Symposium Evaluation

1 Start 2 Complete

Please take a moment to provide feedback about the 2026 Annual Updates in Hematology Symposium. This valuable information will help planners and organizers in the planning of future meetings.

Course Objectives *

Please rate how well course objectives were met for this activity.

	Excellent	Good	Average	Below Average	Poor	N/A
Develop and execute personalized treatment plans for patients with hematologic malignancies and blood disorders by utilizing guideline recommendations based on the evaluation of molecular and phenotypic biomarkers, along with precise disease sub-classification.	Develop and execute personalized treatment plans for patients with hematologic malignancies and blood disorders by utilizing guideline recommendations based on the evaluation of molecular and phenotypic biomarkers, along with precise disease sub-classification. - Excellent	Develop and execute personalized treatment plans for patients with hematologic malignancies and blood disorders by utilizing guideline recommendations based on the evaluation of molecular and phenotypic biomarkers, along with precise disease sub-classification. - Good	Develop and execute personalized treatment plans for patients with hematologic malignancies and blood disorders by utilizing guideline recommendations based on the evaluation of molecular and phenotypic biomarkers, along with precise disease sub-classification. - Average	Develop and execute personalized treatment plans for patients with hematologic malignancies and blood disorders by utilizing guideline recommendations based on the evaluation of molecular and phenotypic biomarkers, along with precise disease sub-classification. - Below Average	Develop and execute personalized treatment plans for patients with hematologic malignancies and blood disorders by utilizing guideline recommendations based on the evaluation of molecular and phenotypic biomarkers, along with precise disease sub-classification. - Poor	Develop and execute personalized treatment plans for patients with hematologic malignancies and blood disorders by utilizing guideline recommendations based on the evaluation of molecular and phenotypic biomarkers, along with precise disease sub-classification. - N/A
Assess the latest clinical trial data on novel agents and emerging strategies for newly diagnosed and relapsed or refractory disease states.	Assess the latest clinical trial data on novel agents and emerging strategies for newly diagnosed and relapsed or refractory disease states. - Excellent	Assess the latest clinical trial data on novel agents and emerging strategies for newly diagnosed and relapsed or refractory disease states. - Good	Assess the latest clinical trial data on novel agents and emerging strategies for newly diagnosed and relapsed or refractory disease states. - Average	Assess the latest clinical trial data on novel agents and emerging strategies for newly diagnosed and relapsed or refractory disease states. - Below Average	Assess the latest clinical trial data on novel agents and emerging strategies for newly diagnosed and relapsed or refractory disease states. - Poor	Assess the latest clinical trial data on novel agents and emerging strategies for newly diagnosed and relapsed or refractory disease states. - N/A
Discuss best strategies in managing treatment-related adverse events through agent familiarity and robust monitoring efforts.	Discuss best strategies in managing treatment-related adverse events through agent familiarity and robust monitoring efforts. - Excellent	Discuss best strategies in managing treatment-related adverse events through agent familiarity and robust monitoring efforts. - Good	Discuss best strategies in managing treatment-related adverse events through agent familiarity and robust monitoring efforts. - Average	Discuss best strategies in managing treatment-related adverse events through agent familiarity and robust monitoring efforts. - Below Average	Discuss best strategies in managing treatment-related adverse events through agent familiarity and robust monitoring efforts. - Poor	Discuss best strategies in managing treatment-related adverse events through agent familiarity and robust monitoring efforts. - N/A

Give one or two examples of patient outcomes that will be directly impacted as a result of participating in this activity. *

What specific changes will you make in your practice/clinical care because of participating in this activity? *

Was the material presented in a manner that was free from commercial bias? *

Yes

No - List commercial bias:

Was the material presented in a manner that was free from commercial bias? No - List commercial bias:

Please provide any additional comments regarding any of the speakers’ content / presentations or suggestions for future topics for this conference.

Leave this field blank

You are here

2026 Annual Updates in Hematology Symposium Evaluation